Protagonist Therapeutics Inc (PTGX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Protagonist Therapeutics Inc stock (PTGX) is currently trading at $104.31. Protagonist Therapeutics Inc PS ratio (Price-to-Sales) is 137.10. Analyst consensus price target for PTGX is $112.42. WallStSmart rates PTGX as Sell.
- PTGX PE ratio analysis and historical PE chart
- PTGX PS ratio (Price-to-Sales) history and trend
- PTGX intrinsic value — DCF, Graham Number, EPV models
- PTGX stock price prediction 2025 2026 2027 2028 2029 2030
- PTGX fair value vs current price
- PTGX insider transactions and insider buying
- Is PTGX undervalued or overvalued?
- Protagonist Therapeutics Inc financial analysis — revenue, earnings, cash flow
- PTGX Piotroski F-Score and Altman Z-Score
- PTGX analyst price target and Smart Rating
Protagonist Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Protagonist Therapeutics Inc (PTGX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in eps growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Protagonist Therapeutics Inc (PTGX) Key Strengths (3)
Earnings per share surging 351.30% year-over-year
114.37% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Protagonist Therapeutics Inc (PTGX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -95.60%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 137.1x annual revenue
Very expensive at 10.3x book value
Supporting Valuation Data
Protagonist Therapeutics Inc (PTGX) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 0.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Market Cap. Growth metrics are encouraging with EPS Growth at 351.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (137.10), Price/Book (10.27) suggest expensive pricing. Growth concerns include Revenue Growth at -95.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -20.20%, Operating Margin at -677.00%, Profit Margin at -282.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -20.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -95.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PTGX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PTGX's Price-to-Sales ratio of 137.10x sits near its historical average of 130.98x (83th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 137.1x set in Mar 2026, and 10% above its historical low of 125.1x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Protagonist Therapeutics Inc (PTGX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Protagonist Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 46M with 96% decline year-over-year. The company is currently unprofitable, posting a -282.8% profit margin.
Key Findings
Spending 101% of revenue (46M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 96% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -282.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 2.24, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Protagonist Therapeutics Inc.
Bottom Line
Protagonist Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Protagonist Therapeutics Inc(PTGX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.